ALGN

Business profile & competitive position

Align Technology, Inc. operates in the Healthcare sector, specifically the Medical – Devices industry, as a global medical device company focused on the design, manufacture, and marketing of Invisalign clear aligners for malocclusion, Vivera retainers, iTero intraoral scanners, related services, and exocad CAD/CAM software used by dental labs and practitioners. Its Align Digital Platform ties these products together into an end-to-end workflow connecting doctors, labs, patients, and consumers. The company sells primarily through a specialized direct sales force to orthodontists, general dental practitioners, labs, and dental support organizations, and supplements that with sales agents and distributors in certain countries.

The revenue mix is heavily tilted toward the core aligner business: the Clear Aligner segment represented roughly 80% of 2025 worldwide net revenues, while Systems and Services contributed roughly 20%. Operationally, more than 95% of Invisalign System prescription orders are now submitted via digital scan, a shift that supports treatment-plan accuracy and shorter turnaround times. Those metrics point to a real digital-installed-base advantage, but the margin picture tempers how wide the moat might be. The company reported a net margin of 10.0% and a return on equity of 10.1%. Those are healthy, positive numbers, yet they are not the kind of outsized, capital-light returns usually associated with a deep pricing-power moat. Instead, they suggest a business that has built switching costs through its scanner-aligner-software ecosystem, but still faces meaningful reinvestment needs and competitive pressure in the orthodontic market.

Financial posture

With a market capitalization of $10.1 billion and a price-to-earnings ratio of 24.4, Align is valued as a growth-oriented medical-device name rather than a mature value stock. The P/E of 24.4 sits at a level that implies the market expects earnings growth to accelerate from today’s 10.0% net margin and 10.1% ROE base, or at least expects the digital-dentistry story to re-rate higher. The stock’s beta is 1.67, well above the market average, which signals that ALGN tends to move substantially more than the broad indexes on macro and sector news.

At the current snapshot of $140.42, the stock is trading below its 50-day exponential moving average of $154.00, and the relative strength index stands at 36.5, near oversold territory but not yet there. That positioning—below a key short-term moving average with compressed momentum—suggests the market is in a wait-and-see mode heading into the next event. Again, the profitability profile is solid (double-digit net margin and ROE), but not so strong that valuation can be taken for granted if growth expectations shift.

Strategic priorities & outlook

Align’s most recent 10-K filing outlines several explicit near-term priorities. The company wants to establish clear aligners as the principal solution for malocclusion and the Invisalign System as the treatment choice for orthodontists, general practitioners, and patients worldwide. It also aims to make iTero intraoral scanners the preferred scanning technology for digital dental scans, and to position exocad CAD/CAM software as the dental restorative solution of choice for dental labs. On the market-share front, Align is focused on increasing its share of the orthodontic case-start market versus traditional wires and brackets, especially among teens, while expanding the overall market for digital orthodontics among adults.

Operationally, the company highlighted that its two segments are Clear Aligner (about 80% of 2025 net revenues) and Systems and Services (about 20%). The filing also noted that Align completed the acquisition of Cubicure in January 2024 to scale direct 3D-printing capabilities, and that it has begun limited manufacturing of certain appliances. Additional devices, including retainers and certain pre-fab attachments, are planned for limited releases in 2026. Those initiatives align with the strategy of tightening the vertical integration between digital scanning, treatment planning, and manufacturing.

Macro & geopolitical exposure

As a Healthcare / Medical – Devices company, Align is exposed to the regulatory framework that governs medical-device clearance and marketing, including U.S. Food and Drug Administration oversight and equivalent foreign regulators. Changes in device classification, approval timelines, or post-market surveillance could affect the pace at which new aligner features, scanner software, or 3D-printed appliances reach the market. Reimbursement and payment dynamics also matter: although clear aligners are partly an elective or cosmetic cash-pay purchase, broader dental benefits, health-spending trends, and consumer discretionary budgets can influence case starts.

Because Align is global, currency fluctuations affect translated international revenue, and supply-chain considerations affect the sourcing of scanner components, polymers, and 3D-printing inputs. Trade policy, including tariffs or export restrictions on manufacturing equipment and raw materials, can move hardware costs and profit margins in either direction. Finally, the dental-device sector is historically litigious on intellectual property, so patent and trade-secret disputes remain a recurring industry risk.

Recent developments

The most concrete near-term catalyst is the third-quarter 2026 earnings report scheduled for October 28, 2026, after the market close, which Align announced on October 1, 2026 via Business Wire.

Heading into that release, sell-side attention picked up. On October 2, 2026, Zacks published “Will Align Technology (ALGN) Beat Estimates Again in Its Next Earnings Report?” and followed it with “These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar.” On October 5, 2026, 247wallst.com included Align in its round-up of Monday’s top Wall Street analyst research calls. That clustering of analyst coverage around the October 28 report underscores that the next earnings update is the focal point for the stock. The current consensus EPS estimate for that release is $2.79.

Earnings behavior & post-earnings drift

Align has a strong historical earnings track record: over the last eight reported quarters, it has beaten estimates seven times, producing an 88% beat rate and an average earnings surprise of 4.7%. The average 5-day price move in the trading days following those reports is 5.26% to the upside, which classifies the post-earnings drift as “up.”

However, the headline beat rate and the average drift hide important variation. Even on beat quarters, the stock has not reliably followed through in the direction of the surprise. The most recent four quarters illustrate that clearly:

• On July 29, 2026, Align reported EPS of $2.64 versus an estimate of $2.62, a 0.8% beat. The stock fell 3.7% the next day and finished the following five days down 2.92%.
• On April 29, 2026, actual EPS was $2.58 versus an estimate of $2.30, a 12.2% beat. The next-day reaction was a 1.34% decline, and the five-day drift was negative 2.5%.
• On February 4, 2026, EPS came in at $3.29 versus $2.99, a 10.0% beat. That time the stock jumped 8.88% the next day and 22.45% over the next five days.
• On October 29, 2025, actual EPS of $2.61 beat the $2.40 estimate by 8.8%, and the stock rose 4.94% the next day and 4.02% over the following five days.

The average 5.26% five-day gain is heavily influenced by the February 2026 outlier; the experience of April and July 2026 shows that a strong beat can still be met with selling if guidance, margins, or the market’s real expectation disappoint. For the October 28, 2026 report, the important number may not be the beat itself but whether results and commentary satisfy the unofficial consensus embedded in the share price.

For a deeper dive into how the sell side is positioned ahead of Align’s October 28, 2026 report, review the full institutional verdict, including analyst rating distributions, price-target range, and recent estimate revisions. That broader context is useful for judging whether current valuation and sentiment already reflect the numbers above.